Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia

-Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria

-Novartis associates rallied behind Power of One to fund close to 500,000 antimalarial treatments for Zambia

-Company reaches delivery landmark with 700 million antimalarial treatments supplied without profit in 60 malaria-endemic countries since 2001

Novartis (http://www.novartis.com) announced today that, through Power of One, enough funds have...

Dr. Linus Igwemezie, Head of the Novartis Malaria Initiative.

 *Malaria experts and leaders from over 35 African countries gather to explore innovative strategies to move from malaria control to elimination

*Meeting convened by Novartis fosters best practice sharing and helps catalyze action to achieve new WHO objective of 90% reduction in malaria burden by 2030

*Growing threats including inadequate funding, first signs of drug resistance, and the advance of diseases such as Ebola, could...

Dr. Linus Igwemezie, Head of the Novartis Malaria Initiative.

WHO prequalified Coartem® 80/480mg is the first and only  high strength malaria treatment available for donor-funded public sector procurement

*WHO prequalified Coartem® 80/480mg is the first and only  high strength malaria treatment available for donor-funded public sector procurement

*Coartem® 80/480mg reduces the pill burden for patients, potentially improving adherence to treatment and clinical outcomes

*This follows the...